Toremifene (CAS 89778-26-7)

Toremifene is a chlorinated tamoxifen analogue which competes with estradiol for estrogen receptors and has growth inhibitory effects on MCF-7 breast cancer cells. Toremifene causes growth inhibition of estrogen-sensitive breast cancer cells by inducing some cells to undergo apoptosis and by inhibiting other cells from entering mitosis. Toremifene, also recognized by the name Fareston, is categorized as a type of organic compound referred to as stilbenes. These compounds are characterized by the presence of a 1,2-diphenylethylene structure. Stilbenes (C6-C2-C6) emerge from the fundamental phenylpropene (C6-C3) framework. When hydroxyl groups are introduced to a phenyl ring, they give rise to stilbenoids. Toremifene is solid in form, exhibiting near-insolubility in water and possessing a relatively neutral nature. This compound has been identified in various biofluids, including urine and blood. Inside the cell, toremifene predominantly resides in the cytoplasm and membrane, a deduction drawn from its logarithm of the partition coefficient (logP). The biosynthesis of toremifene can occur through the transformation of stilbene.